FOXO4-DRI

FOXO4-DRI sits in Caution at 4.2 because it pairs one of the most elegant senolytic mechanisms and the most dramatic mouse result in the category with zero human evidence and grey-market-only sourcing. If you are fascinated by the science, the right move is to watch it, not inject it. The mechanism is real, the Baar 2017 data is real, and the structural follow-up in Bourgeois and Madl 2025 is real. What is missing is any human trial, any registered study, and any human safety data, while the mechanism itself, broad p53 modulation, is a genuine double-edged tool. The hype around this peptide far outruns its proof. If you want a senolytic with human evidence today, the better-supported path runs through fisetin and dasatinib plus quercetin.

✅ Best for: People who follow longevity science closely and want to track an unusually clever senolytic mechanism as it develops. Readers who understand that a striking mouse result is a reason to watch a field, not a reason to inject an unapproved peptide. Anyone comparing senolytic options who wants to see clearly why the human-evidenced choices outscore the famous one. Self-experimenters who, before considering any senolytic, will start with the oral compounds that actually have human data. Curious readers who want the honest version of the regrew fur in old mice story rather than the marketing version.

❌ Avoid if: You have active or suspected cancer, since deliberately modulating p53 and apoptosis with an uncharacterized peptide is exactly the wrong experiment. You expect human-proven anti-aging benefit, because there is none for this compound. You are uncomfortable injecting a grey-market research chemical with no guarantee of sterility, identity, or purity. You want a senolytic you can take orally with early human data behind it, in which case fisetin or dasatinib plus quercetin fit far better. You would read the dramatic mouse data as if it predicts human results, which is the exact error this report exists to prevent.